David Albala discusses the emerging field of telesurgery. Dr. Albala highlights the evolution from traditional surgical training to robotic surgery, and now to telesurgery, where surgeons can operate remotely. He mentions key milestones, including the first transatlantic telesurgery in 1998, and recent advancements in China and Japan. Dr. Albala emphasizes the potential of telesurgery to address…
The FDA’s Center for Biologics Evaluation and Research (CBER), Office of Therapeutic Products (OTP) is hosting a webinar on Thursday, January 30th, 2025 from 1:00…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alicia…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Neal…
Eric Kim discusses the variation in prostate cancer genomic subtypes related to MRI PI-RADS scores and racial differences. He focused on the correlations between mpMRI…
Zachary Klaassen interviews Oliver Sartor about three significant prostate cancer trials presented at ESMO 2024. Dr. Sartor discusses the ARANOTE, PEACE-3, and the SPLASH trials.…
J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large drugmakers
The company listed $1 billion to $10 billion in assets and liabilities each, along with more than 100,000 creditors in a bankruptcy petition.
